James Mulay sold $125k of CGON
director at CG Oncology, Inc.. 1,964 shares at an average of $63.50, traded Mar 16, 2026, filed Mar 17, 2026.
Score components
- +15RoleDirector
- +10Trade size$125k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.4%, 3m -12.2%, 6m +5.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-110831, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +654 | $3.72 | $2,433 | 654 | Mar 17, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -654 | $63.50 | $42k | 0 | Mar 17, 2026 |
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +1,310 | $12.59 | $16k | 1,310 | Mar 17, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -1,310 | $63.50 | $83k | 0 | Mar 17, 2026 |
| Mar 16, 2026 | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -654 | $0.00 | $0 | 654 | Mar 17, 2026 |
| Mar 16, 2026 | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -1,310 | $0.00 | $0 | 3,930 | Mar 17, 2026 |
Related signals
Other insiders at CG Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | CG Oncology, Inc. | Leonard E Post director | $73k 1,000 shares | -100% | |
| 8Weak | CG Oncology, Inc. | Leonard E Post director | $75k 1,000 shares | -100% | |
| 16Weak | CG Oncology, Inc. | Leonard E Post director | $71k 1,000 shares | -100% | |
| 33Weak | CG Oncology, Inc. | James Mulay director | $1.8M 24,165 shares | -100% | |
| 31Weak | CG Oncology, Inc. | Brian Guan-Chyun Liu director | $25M 371,085 shares | +24% | |
| 23Weak | CG Oncology, Inc. | Leonard E Post director | $350k 5,000 shares | -100% | |
| 22Weak | CG Oncology, Inc. | Leonard E Post director | $325k 5,000 shares | -100% | |
| 18Weak | CG Oncology, Inc. | James Mulay director | $118k 1,964 shares | -300% | |
| 15Weak | CG Oncology, Inc. | Leonard E Post director | $55k 1,000 shares | -100% | |
| 25Weak | CG Oncology, Inc. | James Mulay director | $1.1M 15,600 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.